Rising Adoption Of Precision Medicine Driving Growth In The Market Is Supporting Development Across The Vyndaqel Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Will The Market Value Of The Vyndaqel Market Change Between 2026 And 2030?

The vyndaqel market has seen significant expansion in recent years. Its valuation is expected to ascend from $1.9 billion in 2025 to $2.23 billion in 2026, registering a compound annual growth rate (CAGR) of 17.4%. The historical increase in this market can be attributed to the approval of tafamidis, the limited availability of effective attr-cm treatments, enhancements in cardiac imaging diagnostics, the proliferation of rare disease programs, and a rise in cardiology referrals.

The vyndaqel market is anticipated to experience significant expansion in the coming years. It will grow to $4.19 billion in 2030 at a compound annual growth rate (CAGR) of 17.1%. This growth during the forecast period is fueled by an aging global population, increased awareness of amyloid cardiomyopathy, the expansion of specialty cardiology centers, higher adoption of genetic testing, and improving reimbursement support. Key trends shaping the market in this timeframe involve the increasing uptake of transthyretin stabilizers, a rise in attr cardiomyopathy diagnoses, the broadening availability of oral treatments for uncommon cardiac conditions, an intensifying focus on disease-modifying cardiac drugs, and greater utilization of long-term amyloidosis treatment.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21321&type=smp

Which Growth Drivers Are Expected To Support The Vyndaqel Market Forward?

The Vyndaqel market is anticipated to expand due to the increasing acceptance of precision medicine. This approach involves tailoring medical treatment to individual patients based on their genetic, environmental, and lifestyle factors, leading to improved treatment effectiveness and outcomes. Its adoption is on the rise as more patients and healthcare providers prefer personalized therapies that ensure targeted treatment and better management of chronic diseases. Vyndaqel enhances precision medicine by offering a focused therapy for transthyretin amyloidosis (ATTR), ensuring that patients who will benefit most receive the treatment. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the US Food and Drug Administration (FDA) approved 16 novel personalized therapies for patients with rare diseases in 2023, an increase from six in 2022. Consequently, the expanding use of precision medicine is fueling the growth of the Vyndaqel market.

How Does Segment Analysis Break Down The Vyndaqel Market Structure?

The vyndaqel market covered in this report is segmented –

1) By Product Type: Vyndaqel (Tafamidis 20 mg), Vyndamax (Tafamidis 61 mg)

2) By Disease Type: Familial Amyloid Polyneuropathy (FAP), Wild-Type Or Hereditary Transthyretin-Mediated Amyloidosis Cardiomyopathy (ATTR-CM)

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies

Subsegments:

1) By Vyndaqel (Tafamidis 20 mg): Oral Capsules, Once-Daily Dosing Regimen, Chronic Long-Term Therapy Use

2) By Vyndamax (Tafamidis 61 mg): Oral Capsules, Once-Daily Dosing Regimen, Chronic Long-Term Therapy Use

What Trends Are Influencing The Vyndaqel Market?

Leading companies in the vyndaqel market are currently prioritizing facility expansions to manufacture active pharmaceutical ingredients, notably transthyretin stabilizing therapeutics. These efforts aim to improve cardiovascular outcomes and decrease hospitalization rates for patients with ATTR-CM. A transthyretin stabilizing therapeutic is defined as a pharmacological agent engineered to bind with and stabilize transthyretin (TTR) tetramers, thereby preventing their breakdown into misfolded monomers that aggregate and form amyloid deposits. For instance, in November 2024, BridgeBio Pharma, a US-based biopharmaceutical company focused on genetic diseases, launched Attruby (acoramidis). This drug is a near-complete (=90%) transthyretin (TTR) stabilizer designed to address critical challenges in transthyretin amyloid cardiomyopathy (ATTR-CM). Attruby (acoramidis) functions by binding to and stabilizing TTR tetramers, which prevents their dissociation into misfolded monomers responsible for forming amyloid deposits within cardiac tissue. This therapy delivers significant cardiovascular benefits, including a reduction in cardiovascular death and cardiovascular-related hospitalizations, all while preserving TTR’s natural physiological functions. This makes it an effective treatment for improving patient outcomes and managing ATTR-CM.

Which Organizations Are Involved In The Vyndaqel Market?

Major companies operating in the vyndaqel market are Pfizer Inc.

Access The Complete Vyndaqel Market Report:

https://www.thebusinessresearchcompany.com/report/vyndaqel-global-market-report

Which Region Stands As The Largest Contributor To The Vyndaqel Market?

North America was the largest region in the vyndaqel market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the vyndaqel market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Vyndaqel Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=21321&type=smp

Browse Through More Reports Similar to the Global Vyndaqel Market 2026, By The Business Research Company

Virtual Assistant Market Report 2026

https://www.thebusinessresearchcompany.com/report/virtual-assistant-global-market-report

Virtual Data Room Market Report 2026

https://www.thebusinessresearchcompany.com/report/virtual-data-room-global-market-report

Vulvodynia Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/vulvodynia-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795